Literature DB >> 17914030

Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes.

Linda R Peterson1, Pilar Herrero, Janet McGill, Kenneth B Schechtman, Zulfia Kisrieva-Ware, Donna Lesniak, Robert J Gropler.   

Abstract

OBJECTIVE: Normal human myocardium switches substrate metabolism preference, adapting to the prevailing plasma substrate levels and hormonal milieu, but in type 1 diabetes, the myocardium relies heavily on fatty acid metabolism for energy. Whether conditions that affect myocardial glucose use and fatty acid utilization, oxidation, and storage in nondiabetic subjects alter them in type 1 diabetes is not well known. RESEARCH DESIGN AND METHODS: To test the hypotheses that in humans with type 1 diabetes, myocardial glucose and fatty acid metabolism can be manipulated by altering plasma free fatty acid (FFA) and insulin levels, we quantified myocardial oxygen consumption (MVo(2)), glucose, and fatty acid metabolism in nondiabetic subjects and three groups of type 1 diabetic subjects (those studied during euglycemia, hyperlipidemia, and a hyperinsulinemic-euglycemic clamp) using positron emission tomography.
RESULTS: Type 1 diabetic subjects had higher MVo(2) and lower myocardial glucose utilization rate/insulin than control subjects. In type 1 diabetes, glucose utilization increased with increasing plasma insulin and decreasing FFA levels. Myocardial fatty acid utilization, oxidation, and esterification rates increased with increasing plasma FFA. Increasing plasma insulin levels decreased myocardial fatty acid esterification rates but increased the percentage of fatty acids going into esterification.
CONCLUSIONS: Type 1 diabetes myocardium has increased MVo(2) and is insulin resistant during euglycemia. However, its myocardial glucose and fatty acid metabolism still responds to changes in plasma insulin and plasma FFA levels. Moreover, insulin and plasma FFA levels can regulate the intramyocardial fate of fatty acids in humans with type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914030     DOI: 10.2337/db07-1199

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  26 in total

1.  Impaired ATP kinetics in failing in vivo mouse heart.

Authors:  Ashish Gupta; Vadappuram P Chacko; Michael Schär; Ashwin Akki; Robert G Weiss
Journal:  Circ Cardiovasc Imaging       Date:  2010-10-06       Impact factor: 7.792

Review 2.  Facts and figures on CAD assessment with SPECT and PET-CT.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02       Impact factor: 9.236

Review 3.  Imaging diabetes mellitus with coronary computed tomography angiography, cardiovascular magnetic resonance, and positron emission tomography.

Authors:  Maleah Grover-McKay
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

4.  Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans.

Authors:  Linda R Peterson; Ibrahim M Saeed; Janet B McGill; Pilar Herrero; Kenneth B Schechtman; Ratnasiri Gunawardena; Carol L Recklein; Andrew R Coggan; Amanda J DeMoss; Carmen S Dence; Robert J Gropler
Journal:  Obesity (Silver Spring)       Date:  2011-08-04       Impact factor: 5.002

Review 5.  Recent advances in metabolic imaging.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

Review 6.  Diabetic cardiomyopathy, causes and effects.

Authors:  Sihem Boudina; Evan Dale Abel
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

Review 7.  Radionuclide imaging of myocardial metabolism.

Authors:  Linda R Peterson; Robert J Gropler
Journal:  Circ Cardiovasc Imaging       Date:  2010-03       Impact factor: 7.792

8.  Free fatty acid flux measured using [1-11C]palmitate positron emission tomography and [U-13C]palmitate in humans.

Authors:  Qiaojun Han; Yanli Cao; Nicola Gathaiya; Bradley J Kemp; Michael D Jensen
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-10-18       Impact factor: 4.310

Review 9.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Measuring plasma fatty acid oxidation with intravenous bolus injection of 3H- and 14C-fatty acid.

Authors:  Christina Koutsari; Asem H Ali; Manpreet S Mundi; Michael D Jensen
Journal:  J Lipid Res       Date:  2012-10-23       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.